脑胶质瘤血管生成拟态分子机制

doi:10.3760/cma.j.cn371439-20200617-00069

国际肿瘤学杂志 ›› 2021, Vol. 48 ›› Issue (6): 362-365.doi: 10.3760/cma.j.cn371439-20200617-00069

脑胶质瘤血管生成拟态分子机制

郭世豪, 任叶青, 郭庚()

山西医科大学附属第一医院神经外科,太原 030001

收稿日期:2020-06-17 修回日期:2020-07-17 出版日期:2021-06-08 发布日期:2021-06-24
通讯作者: 郭庚 E-mail:guogeng973@163.com
基金资助:
国家自然科学基金(81201991);中国博士后科学基金(2015M571068);中国博士后科学基金(2016T90115);山西省自然科学基金(201601D011127);山西省高等学校创新人才支持计划(2013-8)

Molecular mechanism of vasculogenic mimicry in brain glioma

Guo Shihao, Ren Yeqing, Guo Geng()

Department of Neurosurgery, First Hospital of Shanxi Medical University, Taiyuan 030001, China

Received:2020-06-17 Revised:2020-07-17 Online:2021-06-08 Published:2021-06-24
Contact: Guo Geng E-mail:guogeng973@163.com
Supported by:
National Natural Science Foundation of China(81201991);China Postdoctoral Science Foundation(2015M571068);China Postdoctoral Science Foundation(2016T90115);Natural Science Foundation of Shanxi Province of China(201601D011127);Program for the Outstanding Innovation Teams of Higher Learning Institutions of Shanxi Province of China(2013-8)

摘要/Abstract

摘要：

血管生成拟态是一种不依赖内皮细胞的新的肿瘤血管生成方式,是肿瘤微循环的重要组成部分。脑胶质瘤中血管生成拟态的形成机制复杂多变,多种分子及信号通路(如缺氧诱导因子、基质金属蛋白酶家族等)在其形成过程中相互作用,共同调控血管生成拟态形成。对分子机制的深入研究可为抗血管生成拟态形成的药物研发提供理论基础。

关键词: 神经胶质瘤, 血管生成拟态, 分子机制

Abstract:

Vasculogenic mimicry (VM) is a new tumor angiogenesis mode independent of endothelial cells and an important component of tumor microcirculation. The formation mechanism of VM in glioma is complex and variable. Various molecules and signal pathways (such as hypoxia induction factor and matrix metalloproteasefamily) interact in the formation process, to jointly regulate the formation of VM. The in-depth study of molecular mechanism can provide a theoretical basis for drug research and development against VM formation.

Key words: Glioma, Vasculogenic mimicry, Molecular mechanisms

郭世豪, 任叶青, 郭庚. 脑胶质瘤血管生成拟态分子机制[J]. 国际肿瘤学杂志, 2021, 48(6): 362-365.

Guo Shihao, Ren Yeqing, Guo Geng. Molecular mechanism of vasculogenic mimicry in brain glioma[J]. Journal of International Oncology, 2021, 48(6): 362-365.

参考文献 33

[1]	Wen PY, Reardon DA. Neuro-oncology in 2015: progress in glioma diagnosis, classification and treatment[J]. Nat Rev Neurol, 2016,12(2):69-70. DOI: 10.1038/nrneurol.2015.242.
[2]	Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vaseulogenie mimicry[J]. Am J Pathol, 1999,155(3):739-752. DOI: 10.1016/S0002-9440(10)65173-5. pmid: 10487832
[3]	白驹, 徐志杰, 廖朝亮 , 等. 血管形成拟态在肿瘤中的研究进展[J]. 中南大学学报(医学版), 2017,42(3):357-364. DOI: 10.11817/j.issn.1672-7347.2017.03.020.
[4]	Zhang X, Zhang J, Zhou H, et al. Molecular mechanisms and anticancer therapeutic strategies in vasculogenic mimicry[J]. J Cancer, 2019,10(25):6327-6340. DOI: 10.7150/jca.34171. doi: 10.7150/jca.34171 pmid: 31772665
[5]	Ge H, Luo H. Overview of advances in vasculogenic mimicry—a potential target for tumor therapy[J]. Cancer Manag Res, 2018,10:2429-2437. DOI: 10.2147/CMAR.S164675. doi: 10.2147/CMAR
[6]	El Hallani S, Boisselier B, Peglion F, et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry[J]. Brain, 2010,133(Pt 4):973-982. DOI: 10.1093/brain/awq044. doi: 10.1093/brain/awq044
[7]	Sun W, Fan YZ, Zhang WZ, et al. A pilot histomorphology and hemodynamic of vasculogenic mimicry in gallbladder carcinomas in vivo and in vitro[J]. J Exp Clin Cancer Res, 2011,30(1):46. DOI: 10.1186/1756-9966-30-46. doi: 10.1186/1756-9966-30-46
[8]	Williamson SC, Metcalf RL, Trapani F, et al. Vasculogenic mimicry in small cell lung cancer[J]. Nat Commu, 2016,7:13322. DOI: 10.1038/ncomms13322.
[9]	Angara K, Rashid MH, Shankar A, et al. Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies[J]. Histol Histopathol, 2017,32(9):917-928. DOI: 10.14670/HH-11-856.
[10]	Yang J, Zhu DM, Zhou XG, et al. HIF-2α promotes the formation of vasculogenic mimicry in pancreatic cancer by regulating the binding of Twist1 to the VE-cadherin promoter[J]. Oncotarget, 2017,8(29):47801-47815. DOI: 10.18632/oncotarget.17999. doi: 10.18632/oncotarget.v8i29
[11]	Li J, Ke Y, Huang S, et al. Inhibitory effects of B-cell lymphoma 2 on the vasculogenic mimicry of hypoxic human glioma cells[J]. ExTher Med, 2015,9(3):977-981. DOI: 10.3892/etm.2014.2162.
[12]	Guo X, Xu S, Gao X, et al. Macrophage migration inhibitory factor promotes vasculogenic mimicry formation induced by hypoxia via CXCR4/AKT/EMT pathway in human glioblastoma cells[J]. Oncotarget, 2017,8(46):80358-80372. DOI: 10.18632/oncotarget.18673. doi: 10.18632/oncotarget.v8i46
[13]	Zhu Y, Liu X, Zhao P, et al. Celastrol suppresses glioma vasculogenic mimicry formation and angiogenesis by blocking the PI3K/Akt/mTOR signaling pathway[J]. Front Pharmacol, 2020,11:25. DOI: 10.3389/fphar.2020.00025. doi: 10.3389/fphar.2020.00025
[14]	Li X, Xue Y, Liu X, et al. ZRANB2/SNHG20/FOXK1 Axis regulates vasculogenic mimicry formation in glioma[J]. J Exp Clin Can-cer Res, 2019,38(1):68. DOI: 10.1186/s13046-019-1073-7.
[15]	Delgado-Bellido D, Serrano-Saenz S, Fernández-Cortés M, et al. Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin[J]. Mol Cancer, 2017,16(1):65. DOI: 10.1186/s12943-017-0631-x. doi: 10.1186/s12943-017-0631-x pmid: 28320399
[16]	Liu S, Zhang SM, Ju RJ, et al. Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma[J]. Eur J Phar Sci, 2017,106:185-197. DOI: 10.1016/j.ejps.2017.06.002.
[17]	Liu X, Wang JH, Li S, et al. Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide 3-kinase/ERK-MMP-laminin5γ2 signaling pathway[J]. Cancer Sci, 2015,106(7):857-866. DOI: 10.1111/cas.12684. doi: 10.1111/cas.2015.106.issue-7
[18]	Guo J, Cai H, Liu X, et al. Long non-coding RNA LINC00339 stimulates glioma vasculogenic mimicry formation by regulating the miR-539-5p/TWIST1/MMPs axis[J]. Mol Ther Nucleic Acids, 2018,10:170-186. DOI: 10.1016/j.omtn.2017.11.011. doi: 10.1016/j.omtn.2017.11.011
[19]	Zhang L, Xu Y, Sun J, et al. M2-like tumor-associated macrophages drive vasculogenic mimicry through amplification of IL-6 expre-ssion in glioma cells[J]. Oncotarget, 2017,8(1):819-832. DOI: 10.18632/oncotarget.13661. doi: 10.18632/oncotarget.13661 pmid: 27903982
[20]	Yu W, Ding J, He M, et al. Estrogen receptor β promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer[J]. Oncogene, 2019,38(8):1225-1238. DOI: 10.1038/s41388-018-0463-1. doi: 10.1038/s41388-018-0463-1
[21]	Li G, Huang M, Cai Y, et al. miR-141 inhibits glioma vasculogenic mimicry by controlling EphA2 expression[J]. Mol Med Rep, 2018,18(2):1395-1404. DOI: 10.3892/mmr.2018.9108.
[22]	Gao Y, Yu H, Liu Y, et al. Long non-coding RNA HOXA-AS2 regulates malignant glioma behaviors and vasculogenic mimicry formation via the MiR-373/EGFR axis[J]. Cell Physiol Biochem, 2018,45(1):131-147. DOI: 10.1159/000486253. doi: 10.1159/000486253
[23]	Wang D, Zheng J, Liu X, et al. Knockdown of USF1 inhibits the vasculogenic mimicry of glioma cells via stimulating SNHG16/miR-212-3p and linc00667/miR-429 axis[J]. Mol Ther Nucleic Acids, 2019,14:465-482. DOI: 10.1016/j.omtn.2018.12.017. doi: 10.1016/j.omtn.2018.12.017
[24]	Yang J, Lu Y, Lin YY, et al. Vascular mimicry formation is promoted by paracrine TGF-β and SDF1 of cancer-associatedfibroblasts and inhibited by miR-101 in hepatocellular carcinoma[J]. Cancer Lett, 2016,383(1):18-27. DOI: 10.1016/j.canlet.2016.09.012. doi: 10.1016/j.canlet.2016.09.012
[25]	Ling G, Wang S, Song Z, et al. Transforming growth factor-β is required for vasculogenic mimicry formation in glioma cell line U251MG[J]. Cancer Biol Ther, 2011,12(11):978-988. DOI: 10.4161/cbt.12.11.18155. doi: 10.4161/cbt.12.11.18155
[26]	Ling G, Ji Q, Ye W, et al. Epithelial-mesenchymal transition regulated by p38/MAPK signaling pathways participates in vasculogenic mimicry formation in SHG44 cells transfected with TGF-β cDNA loaded lentivirus in vitro and in vivo[J]. Int J Oncol, 2016,49(6):2387-2398. DOI: 10.3892/ijo.2016.3724. doi: 10.3892/ijo.2016.3724
[27]	Zhang C, Chen WL, Zhang X, et al. Galunisertib inhibits glioma vasculogenic mimicry formation induced by astrocytes[J]. Sci Rep, 2016,6:23056. DOI: 10.1038/srep23056. doi: 10.1038/srep23056
[28]	Cai HP, Wang J, Xi SY, et al. Tenascin-cmediated vasculogenic mimicry formation via regulation of MMP2/MMP9 in glioma[J]. Cell Death Dis, 2019,10(12):879. DOI: 10.1038/s41419-019-2102-3. doi: 10.1038/s41419-019-2102-3
[29]	Liu Y, Li F, Yang YT, et al. IGFBP2 promotes vasculogenic mimicry formation via regulating CD144 and MMP2 expression in glioma[J]. Oncogene, 2019,38(11):1815-1831. DOI: 10.1038/s41388-018-0525-4. doi: 10.1038/s41388-018-0525-4 pmid: 30368528
[30]	Zhang F, Chu J, Wang F. Expression and clinical significance of cyclooxygenase 2 and survivin in human gliomas[J]. Oncol Lett, 2017,14(2):1303-1308. DOI: 10.3892/ol.2017.6281. doi: 10.3892/ol.2017.6281 pmid: 28789345
[31]	Rong X, Huang B, Qiu S, et al. Tumor-associated macrophages induce vasculogenic mimicry of glioblastoma multiforme through cyclooxygenase-2 activation[J]. Oncotarget, 2016,7(51):83976-83986. DOI: 10.18632/oncotarget.6930. doi: 10.18632/oncotarget.v7i51
[32]	Ju RJ, Zeng F, Liu L, et al. Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma[J]. Int J Nanomedicine, 2016,11:1131-1146. DOI: 10.2147/IJN.S94467.
[33]	Huang M, Ke Y, Sun X, et al. Mammalian target of rapamycin signaling is involved in the vasculogenic mimicry of glioma via hypoxia-inducible factor-1α[J]. Oncol Rep, 2014,32(5):1973-1980. DOI: 10.3892/or.2014.3454. doi: 10.3892/or.2014.3454

脑胶质瘤血管生成拟态分子机制

Molecular mechanism of vasculogenic mimicry in brain glioma

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 33

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[2]	肖楠, 孙鹏飞. 氧化应激在胶质瘤放化疗敏感性中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 357-361.
[3]	孔春禹, 孙鹏飞. SLC7A11与胶质瘤[J]. 国际肿瘤学杂志, 2022, 49(10): 604-607.
[4]	杨驰, 罗长江. 结直肠癌炎症、免疫及胆固醇代谢背景研究进展[J]. 国际肿瘤学杂志, 2022, 49(10): 630-634.
[5]	王宪伟, 史美燕, 王凤芹, 齐福, 王朝喆, 周飞. TSA上调miR-4298靶向抑制PADI4表达在诱导U251细胞凋亡中的作用[J]. 国际肿瘤学杂志, 2021, 48(4): 193-199.
[6]	张雯, 胡伟国, 宋启斌. 3D-ASL与DCE-MRI在脑胶质瘤复发与放射性脑坏死鉴别诊断中的价值[J]. 国际肿瘤学杂志, 2021, 48(10): 631-634.
[7]	赵聪选, 于韬. 胶质瘤相关基因的挖掘及预测[J]. 国际肿瘤学杂志, 2020, 47(5): 293-296.
[8]	苏昊, 刘文杰, 包满都拉, 罗寿, 王雪玮, 赵传多, 刘骞, 王锡山, 周志祥, 周海涛. 转移性结直肠癌西妥昔单抗耐药的分子机制[J]. 国际肿瘤学杂志, 2020, 47(5): 308-311.
[9]	南阳, 钟跃. 长非编码RNA在神经胶质瘤研究中的新进展[J]. 国际肿瘤学杂志, 2020, 47(2): 98-102.
[10]	张雯, 宋启斌, 胡伟国. 多模态磁共振成像在脑胶质瘤中的临床应用[J]. 国际肿瘤学杂志, 2020, 47(11): 686-690.
[11]	陈亮, 秦军, 雷军荣, 刘俊, 王璐. miR-1254通过靶向CSF-1抑制胶质瘤细胞的增殖和侵袭能力[J]. 国际肿瘤学杂志, 2020, 47(10): 577-584.
[12]	张千慧, 张洋, 宿伟鹏, 张宋安, 刘攀, 赵化荣. LSD1、MGMT和Ki-67在高级别胶质瘤中的表达及对预后的影响[J]. 国际肿瘤学杂志, 2019, 46(9): 519-525.
[13]	衣琳, 邱实. 紫草素抗胶质瘤效应及其作用机制[J]. 国际肿瘤学杂志, 2019, 46(8): 489-491.
[14]	于学娟, 安宏伟, 孙亚梅, 姜政, 张学海, 杨文敬, 张伟. MMP2、TIMP2、Ki-67、P53在胶质瘤组织中的表达及意义 [J]. 国际肿瘤学杂志, 2019, 46(12): 718-722.
[15]	卢迪,张钧栋,郭庚,王小刚. 干扰素通路中的关键分子诱导脑胶质瘤细胞凋亡的机制[J]. 国际肿瘤学杂志, 2018, 45(7): 432-435.